The White House is threatening yet another change to the childhood vaccine schedule in line with Secretary of Health and Human Services secretary Robert F. Kennedy Jr.’s MAHA agenda.  | The president ...

Bayer has decided to offload its aging cancer drug Stivarga to German compatriot Grünenthal as competition mounts. | Bayer has decided to offload its aging cancer drug Stivarga to German compatriot ...

IntraBio is on a roll with its expansion plans for chemically altered amino acid, Aqneursa. | IntraBio's streak of success in the rare neurological category continues, as the drugmaker racks up a ...

Novo CEO Mike Doustdar faced a tough crowd as the Danish pharma gathered investors in London this morning for the compan | With reports leaking out of investor discontent, CEO Mike Doustdar opened ...

Public Citizen stressed that it supports efforts to lower drug costs for people in America, while caveating that the MFN deals as understood—and with added color from companies on the policy’s ...

Much like GSK (formerly GlaxoSmithKline) and the once Sanofi-Aventis (now just Sanofi), Novo Nordisk is slimming down its ...

Eli Lilly is sharpening its competitive edge in the crowded oral SERD arena as the FDA has approved a combination of its ...

Novo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker last year after losing GLP-1 marketing ground to ...

Roche’s T-cell engager portfolio has notched another milestone, as a phase 3 trial of the company’s Lunsumio met its primary ...

Most drug licensing deals with China will be safe from rules being drafted by the U.S. Treasury Department, Reuters reports.

In a push to free itself up for more R&D, Sanofi is acquiring a stake in German drugmaker, Cheplapharm. | In a deal that ...

In their lawsuit, BMS and Ono accuse Amgen of aiming to market its biosimilar ahead of the expiration of key U.S. patents ...